熊去氧胆酸治疗不同临床分期原发性胆汁性肝硬化患者2年临床疗效观察

doi:10.3969/j.issn.1672-5069.2014.04.026

Abstract

Jiang Longzhong, Chen Liang, Chen Yi. A two-year clinical study on the efficacy of ursodeoxycholic acid on primary biliary cirrhosis in different stages[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(4): 422-425.

References

[1] Selmi C,Bowlus CL,Cershwin ME,et al. Primary biliary cirrhosis. Lancet,2011,377（9777）:1600-1609.
[2] 贾继东,段维佳.原发性胆汁性肝硬化的研究进展. 中华肝脏病杂志,2011,19（5）：321-322.
[3] 柴煊,涂波. 熊去氧胆酸治疗原发性胆汁性肝硬化32例临床疗效评价. 武警医学院学报,2011,20（9）：23-24.
[4] 赵素贤,赵景民. 原发性胆汁性肝硬化发病机制的研究. 临床肝胆病杂志,2007,23（5）：395-397.
[5] 陆伦根,曾民德.胆汁淤积性肝病. 北京:人民卫生出版社,2007：169-181.
[6] Heathcote EJ.Management of primary bilary cirrhosis.The Amerian Association for the Study of Liver Diseases:Practice guidelines. Hepatology,2000,31（4）:1005-1013.
[7] 王宝恩,张定风.现代肝脏病学. 北京：科学出版社,2003：366.
[8] Corpechot C,Abenavoli L,Rabahi N,et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology,2008,48（3）:871-877.
[9] Pares A,Caballeria L,Rodes J.Excellent long-term survival in patients with primary biliary cirrosis and biochemical response to ursodeoxycholic Acid. Gastroenterology,2006,130（3）:715-720.
[10] 泽塔多吉,吕洪敏,向慧玲,等. 肝硬化期原发性胆汁性肝硬化患者的临床特点及预后分析. 山东医药,2011,51（45）：57-59.
[11] Poupon R.Treatmeant of primary biliary cirrhosis with ursodeoxycholic acid,budesonide and fibrates. Dig Dis,2011,29（1）:85-88.
[12] 张福奎,贾继东,王宝恩,等. 45例原发性胆汁性肝硬化的临床特点. 中华内科杂志,2002,41（3）：163-167.
[13] Leuschner M,Dietrich CF. Characterization of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut,2000,46（1）:121-126.
[14] Inoue K,Hirohara J,Nakano T,et al.Prediction of progosis of primary biliary cirrhosis in Japan.Liver,1995,15（2）:70-77.
[15] 熊玮,张艳玲,杨春珍. 还原性谷胱甘肽治疗药物性肝炎的疗效观察. 内蒙古中医药,2012,31（16）：76-77.
[16] Liador KD,Cerahwin ME,Poupon R.et al. AASLD practice guidelines:primary biliary cirrhosis. Hepatology,2009,50（1）:291-308.
[17] European Association for the Study of the Liver. EASL clinical practice guidelines:management of cholestatic liver diseases. Hepatology,2009,51（2）:237-267.
[18] Kim KA,Jeong SH. The diagnosis and treatment of primary biliary cirrhosis. Kor J Hepatol,2011,17（3）:173-179.
[19] Tanaka A,Harada K,Ebinuma H. et al.Primary biliary cirrhosis Autoimmune hepatitis overlap syndrome:A rationale for corticosteroids use based on a nation-wide retrospective study in Japan. Hepatol Hes,2011.41（9）:877-886.
[20] SHI J,WU C,LIN Y,et al. Long-term effects of mid_dose ursodeoxycholic acid in primary biliary cirrhosis:a mata analysis of randomized controlled trials. Am J Gastroenterol,2006,101（7）:1529-1538.
[21] Corpechot C,Chazouileres O,Poupon R. Early primary biliary cirrhosis:biochemical response to treatment and prediction of long-term outcome. Hepatology,2011,55（6）:1361-1367.
[22] 施健,刘苏,陈伟志,等. 中等剂量UDCA治疗原发性肝胆汁性肝硬化的系统评价. 中华消化杂志,2005,25（6）：355-358.
[23] 袁淑芳,刘桂桃,杜新. 熊去氧胆酸在原发性胆汁性肝硬化的疗效分析. 新疆医学,2012,42（1）：1-3.

A two-year clinical study on the efficacy of ursodeoxycholic acid on primary biliary cirrhosis in different stages

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[3]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[4]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[5]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[6]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[7]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[8]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[9]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[10]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[11]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[12]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[13]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[14]	Jin Lianghong, Li Xingjie, Guan Hongbo, et al. Clinical value of dual-energy CT iodine quantification combined with dynamic contrast-enhanced MRI in evaluating hepatic hemodynamics and liver functions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 712-715.
[15]	Bian Xinqu, Chen Jie, Liu Yanmin, et al. Serum thyroid hormone level changes in patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy [J]. Journal of Practical Hepatology, 2019, 22(5): 716-719.